Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

SAB Biotherapeutics (SABS) Operating Margin: 2021-2025

Historic Operating Margin for SAB Biotherapeutics (SABS) over the last 5 years, with Sep 2025 value amounting to 29,287.09%.

  • SAB Biotherapeutics' Operating Margin rose 1479460.00% to 29,287.09% in Q3 2025 from the same period last year, while for Sep 2025 it was 69,102.73%, marking a year-over-year increase of 7271157.00%. This contributed to the annual value of -3,244.87% for FY2024, which is 154432.00% down from last year.
  • SAB Biotherapeutics' Operating Margin amounted to 29,287.09% in Q3 2025, which was up 93.64% from 15,124.81% recorded in Q2 2025.
  • SAB Biotherapeutics' Operating Margin's 5-year high stood at 29,287.09% during Q3 2025, with a 5-year trough of -8,726.26% in Q4 2024.
  • Its 3-year average for Operating Margin is 4,102.29%, with a median of -1,205.90% in 2024.
  • Its Operating Margin has fluctuated over the past 5 years, first slumped by 747,037bps in 2023, then surged by 1,900,177bps in 2025.
  • Quarterly analysis of 5 years shows SAB Biotherapeutics' Operating Margin stood at -66.41% in 2021, then plummeted by 29,733bps to -363.74% in 2022, then crashed by 582,416bps to -6,187.90% in 2023, then slumped by 253,836bps to -8,726.26% in 2024, then skyrocketed by 1,479,460bps to 29,287.09% in 2025.
  • Its Operating Margin was 29,287.09% in Q3 2025, compared to 15,124.81% in Q2 2025 and 15,484.95% in Q1 2025.